EV/EBITDA spoločnosti SinoMab BioScience
Aká je hodnota metriky EV/EBITDA spoločnosti SinoMab BioScience?
Hodnota metriky EV/EBITDA spoločnosti SinoMab BioScience Limited je N/A
Aká je definícia metriky EV/EBITDA?
EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA spoločností v sektore Health Care sektor na HKSE v porovnaní so spoločnosťou SinoMab BioScience
Čomu sa venuje spoločnosť SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou ev/ebitda podobnou spoločnosti SinoMab BioScience
- Hodnota metriky EV/EBITDA spoločnosti Novavax je N/A
- Hodnota metriky EV/EBITDA spoločnosti Cazaly Resources je N/A
- Hodnota metriky EV/EBITDA spoločnosti DC Acquisition je N/A
- Hodnota metriky EV/EBITDA spoločnosti Macarthur Minerals je N/A
- Hodnota metriky EV/EBITDA spoločnosti Sierra Madre Gold and Silver je N/A
- Hodnota metriky EV/EBITDA spoločnosti Rathdowney Resources je N/A
- Hodnota metriky EV/EBITDA spoločnosti SinoMab BioScience je N/A
- Hodnota metriky EV/EBITDA spoločnosti Big Dougie Capital je N/A
- Hodnota metriky EV/EBITDA spoločnosti Income Trust je N/A
- Hodnota metriky EV/EBITDA spoločnosti Aloro Mining je N/A
- Hodnota metriky EV/EBITDA spoločnosti Manganese X je N/A
- Hodnota metriky EV/EBITDA spoločnosti Coho Collective Kitchens je N/A
- Hodnota metriky EV/EBITDA spoločnosti Viva Gold je N/A